Physician profile
Ayate Kaced
NPI 1346905296
$8,961.31
in general payments reported to CMS, 2019-2025
28 companies · $4,547 in 2025
The $4,547 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $128 · 2023: $372 · 2024: $3,914 · 2025: $4,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,247 · Education: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,246.89 |
| Education | $586.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,124.34 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $1,111.79 | 2023-2025 | Odomzo, Blu-U, Winlevi |
| Incyte Corporation | $964.51 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $837.75 | 2024-2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $766.24 | 2023-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $666.71 | 2024-2025 | |
| Ucb, INC. | $620.12 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $427.06 | 2023-2025 | Cabtreo, Jublia, Siliq |
| Regeneron Healthcare Solutions, INC. | $344.83 | 2024-2025 | Dupixent, Libtayo |
| Pfizer INC. | $293.57 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $278.08 | 2024-2025 | Sotyktu |
| Lilly USA, LLC | $217.19 | 2023-2025 | Ebglyss, Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $185.10 | 2025 | |
| Leo Pharma INC. | $145.42 | 2024-2025 | Adbry |
| Janssen Pharmaceuticals, INC | $128.21 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $126.62 | 2024 | Vtama |
| Amgen INC. | $123.97 | 2024-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $115.01 | 2025 | |
| Botanix Sb INC | $108.26 | 2025 | Sofdra |
| Organon LLC | $105.04 | 2024-2025 | Hadlima |
| Arcutis Biotherapeutics, INC. | $82.72 | 2024-2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $55.43 | 2025 | Valchlor |
| Sanofi US Services INC. | $32.07 | 2024 | |
| Journey Medical Corporation | $29.74 | 2023-2025 | |
| Fidia Pharma USA INC. | $21.35 | 2024 | |
| Blueprint Medicines Corporation | $18.31 | 2024 | Ayvakit |
| Lnhc, INC | $17.91 | 2025 | Zelsuvmi |
| Strata Skin Sciences, INC. | $13.96 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayate Kaced listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.